Novel targeted therapy for advanced renal carcinoma: trials in progress

Related Experiment Video

Updated: Jun 11, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Fabio Calabrò1, Cora N Sternberg

  • 1San Camillo Forlanini Hospital, Padiglione Flajani, Rome, Italy. cstern@mclink.it

Current Opinion in Urology
|July 14, 2010
PubMed
Abstract

Insights

Targeted therapies have transformed metastatic renal cell carcinoma treatment. Recent clinical trials show improved outcomes with drugs inhibiting key cancer pathways, with ongoing research exploring combinations and new agents.

Area of Science:

  • Oncology
  • Translational Medicine
  • Pharmacology

Background:

  • Advances in understanding renal cell carcinoma (RCC) biology.
  • Emergence of targeted therapies for metastatic RCC.
  • Shift towards personalized treatment strategies.

Purpose of the Study:

  • To review recently reported and ongoing clinical trials in metastatic RCC.
  • To define the role of novel targeted drugs in RCC management.
  • To provide an updated survey of therapeutic advancements.

Main Methods:

  • Systematic review of clinical trial data.
  • Analysis of randomized phase III clinical trials.
  • Evaluation of targeted agents and their mechanisms of action.

Main Results:

  • Several targeted therapies (sunitinib, sorafenib, bevacizumab, pazopanib, temsirolimus, everolimus) have improved outcomes.
  • These agents target critical pathways including VEGF, tyrosine kinases, and mTOR.
  • Significant progress in managing metastatic renal cell carcinoma.

Conclusions:

  • Combinations and sequences of targeted agents are under investigation.
  • Novel agents targeting new pathways are in clinical development.
  • Ongoing trials will clarify the role of cytoreductive nephrectomy and adjuvant treatments.

More Related Videos

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.